This replenishment seeks to raise at least $14 billion to help save 16 million lives, avert 234 million infections and help the world get back on track to end these diseases.
The Global Fund is calling on the private sector to mobilise at least $1 billion to step up the fight.
MedAccess has been invited to showcase how a social finance company can accelerate the delivery of new and better products in the fight against these diseases.
CEO Michael Anderson will join a panel discussion with pharmaceutical companies Sanofi and ViiV Healthcare.
Here, he will discuss how MedAccess guarantees will help to make quality health products more accessible at lower prices, enabling patients to live longer and healthier lives.
Michael will also announce a fresh injection of $100 million of paid-in capital from our parent company, CDC Group.
This capital will allow MedAccess to further its mission of bringing affordable and accessible health products to more people in a wider range of countries.
MedAccess, CHAI and SD Biosensor announce partnership to make dual rapid test for syphilis and HIV available for under US$1 in over 100 low- and middle-income countries
Vicky will lead on all aspects of financial management, control and reporting and she joins MedAccess' Senior Management Team.
MedAccess' volume guarantee will help increase availability of an innovative treatment for latent tuberculosis.